Hoikka V, Alhava E M, Aro A, Karjalainen P, Rehnberg V
Acta Med Scand. 1980;207(3):221-4. doi: 10.1111/j.0954-6820.1980.tb09709.x.
A double-blind comparative study of 1 alpha-OHD3 and placebo was performed on 37 patients with osteoporotic hip fracture without clinical osteomalacia. 1 alpha-OHD3, in a dose of 1 microgram/day together with 2.5 g CaCO3, did not heal osteoporosis as judged from determinations of bone mineral density and histomorphometric analyses during four months of treatment. However, 1 alpha-OHD3 seemed to have an effect on fracture healing as concluded from the posttreatment alkaline phosphatase level. Hypercalcemia was common, occurring in six out of 19 patients treated with 1 alpha-OHD3. It is concluded that treatment of osteoporosis with 1 alpha-OHD3 and calcium is ineffective and potentially dangerous because it frequently causes hypercalcemia.
对37例无临床骨软化症的骨质疏松性髋部骨折患者进行了1α-羟化胆钙化醇（1α-OHD3）与安慰剂的双盲对照研究。在为期四个月的治疗期间，通过骨密度测定和组织形态计量学分析判断，每日剂量为1微克的1α-OHD3联合2.5克碳酸钙并不能治愈骨质疏松症。然而，从治疗后碱性磷酸酶水平得出的结论是，1α-OHD3似乎对骨折愈合有影响。高钙血症很常见，在接受1α-OHD3治疗的19例患者中有6例出现。得出的结论是，用1α-OHD3和钙治疗骨质疏松症无效且有潜在危险，因为它经常导致高钙血症。
